Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GPCR Structure Therapeutics	$20.62 +0.9%	$23.28	$13.22 ▼ $47.48	$1.17B	-1.87	835,751 shs	372,490 shs
OCUL Ocular Therapeutix	$9.36 -1.1%	$8.16	$5.79 ▼ $11.78	$1.51B	1.43	1.41 million shs	1.16 million shs
SPRY ARS Pharmaceuticals	$16.49 -1.6%	$14.76	$8.86 ▼ $18.90	$1.65B	0.9	1.34 million shs	881,491 shs
TKNO Alpha Teknova	$5.22 +2.6%	$5.98	$1.16 ▼ $10.37	$272.01M	0.33	421,228 shs	147,080 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GPCR Structure Therapeutics	-0.34%	-6.20%	-6.20%	+25.17%	-47.22%
OCUL Ocular Therapeutix	+3.96%	+2.94%	+16.65%	+35.14%	+41.62%
SPRY ARS Pharmaceuticals	+4.10%	-2.95%	+15.84%	+25.00%	+93.42%
TKNO Alpha Teknova	+3.25%	-1.93%	-11.17%	+4.52%	+313.82%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GPCR Structure Therapeutics	2.9495 of 5 stars	3.5	3.0	0.0	2.8	1.7	0.6
OCUL Ocular Therapeutix	3.7997 of 5 stars	3.5	1.0	4.1	2.0	2.5	0.0
SPRY ARS Pharmaceuticals	3.1097 of 5 stars	3.6	1.0	0.0	2.7	4.2	0.6
TKNO Alpha Teknova	3.0464 of 5 stars	3.5	3.0	0.0	3.1	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GPCR Structure Therapeutics	3.00	Buy	$76.17	269.40% Upside
OCUL Ocular Therapeutix	3.00	Buy	$17.33	85.19% Upside
SPRY ARS Pharmaceuticals	3.17	Buy	$31.00	88.05% Upside
TKNO Alpha Teknova	3.00	Buy	$8.50	62.84% Upside

Current Analyst Ratings Breakdown

Latest TKNO, SPRY, GPCR, and OCUL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/23/2025	GPCR Structure Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$65.00
6/23/2025	GPCR Structure Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$89.00
5/29/2025	OCUL Ocular Therapeutix	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00
5/12/2025	GPCR Structure Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$80.00 ➝ $75.00
5/6/2025	OCUL Ocular Therapeutix	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $14.00
5/2/2025	GPCR Structure Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$60.00
4/22/2025	GPCR Structure Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
4/8/2025	OCUL Ocular Therapeutix	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
4/8/2025	OCUL Ocular Therapeutix	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $15.00

(Data available from 7/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GPCR Structure Therapeutics	N/A	N/A	N/A	N/A	$15.10 per share	N/A
OCUL Ocular Therapeutix	$63.72M	23.40	N/A	N/A	$2.01 per share	4.66
SPRY ARS Pharmaceuticals	$89.15M	18.16	$0.01 per share	1,977.96	$2.64 per share	6.24
TKNO Alpha Teknova	$37.74M	7.39	N/A	N/A	$1.55 per share	3.37

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GPCR Structure Therapeutics	-$122.53M	-$0.87	0.00	N/A	N/A	N/A	-16.35%	-15.71%	8/6/2025 (Estimated)
OCUL Ocular Therapeutix	-$193.51M	-$1.15	N/A	N/A	N/A	-323.09%	-59.92%	-41.98%	8/6/2025 (Estimated)
SPRY ARS Pharmaceuticals	$8M	-$0.16	0.00	N/A	N/A	-16.11%	-6.94%	-5.60%	8/5/2025 (Estimated)
TKNO Alpha Teknova	-$26.75M	-$0.48	0.00	N/A	N/A	-60.90%	-28.48%	-19.73%	8/12/2025 (Estimated)

Latest TKNO, SPRY, GPCR, and OCUL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	SPRY ARS Pharmaceuticals	-$0.35	-$0.35	N/A	-$0.35	$7.48 million	$7.97 million
5/8/2025	Q1 2025	GPCR Structure Therapeutics	-$0.24	-$0.27	-$0.03	-$0.27	N/A	N/A
5/8/2025	Q1 2025	TKNO Alpha Teknova	-$0.11	-$0.09	+$0.02	-$0.09	$9.41 million	$9.60 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GPCR Structure Therapeutics	N/A	N/A	N/A	N/A	N/A
OCUL Ocular Therapeutix	N/A	N/A	N/A	N/A	N/A
SPRY ARS Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TKNO Alpha Teknova	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GPCR Structure Therapeutics	N/A	23.29	23.29
OCUL Ocular Therapeutix	0.26	10.22	10.14
SPRY ARS Pharmaceuticals	0.30	11.00	10.74
TKNO Alpha Teknova	0.17	5.64	4.71

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GPCR Structure Therapeutics	91.78%
OCUL Ocular Therapeutix	59.21%
SPRY ARS Pharmaceuticals	68.16%
TKNO Alpha Teknova	13.81%

Insider Ownership

Company	Insider Ownership
GPCR Structure Therapeutics	9.43%
OCUL Ocular Therapeutix	2.30%
SPRY ARS Pharmaceuticals	33.50%
TKNO Alpha Teknova	12.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GPCR Structure Therapeutics	136	57.34 million	51.94 million	Optionable
OCUL Ocular Therapeutix	230	159.30 million	155.64 million	Optionable
SPRY ARS Pharmaceuticals	90	98.21 million	65.31 million	Optionable
TKNO Alpha Teknova	240	53.44 million	46.76 million	Not Optionable

TKNO, SPRY, GPCR, and OCUL Headlines

Recent News About These Companies

Martha J. Demski Sells 8,000 Shares of Alpha Teknova, Inc. (NASDAQ:TKNO) Stock

July 2 at 6:04 AM | insidertrades.com

Alpha Teknova, Inc. (NASDAQ:TKNO) Director Sells $40,480.00 in Stock

July 1 at 6:07 PM | marketbeat.com

Alpha Teknova, Inc. (TKNO) Income Statement - Yahoo Finance

June 28, 2025 | ca.finance.yahoo.com

Conestoga Capital Advisors LLC Sells 52,070 Shares of Alpha Teknova, Inc. (NASDAQ:TKNO)

June 17, 2025 | marketbeat.com

Alpha Teknova, Inc. (NASDAQ:TKNO) Q1 2025 Earnings Call Transcript

May 10, 2025 | msn.com

Alpha Teknova, Inc. (TKNO) Q1 2025 Earnings Call Transcript

May 10, 2025 | seekingalpha.com

Teknova Reports First Quarter 2025 Financial Results

May 8, 2025 | globenewswire.com

Alpha Teknova (TKNO) Traded Lower on Increased Uncertainty

April 30, 2025 | msn.com

Alpha Teknova, Inc. to Report First Quarter Financial Results on May 8, 2025

April 24, 2025 | quiverquant.comQ

Teknova to Report First Quarter 2025 Financial Results on May 8, 2025

April 24, 2025 | globenewswire.com

Alpha Teknova, Pluristyx launch proprietary PluriFreeze cryopreservation system

March 20, 2025 | markets.businessinsider.com

Teknova and Pluristyx Launch Proprietary PluriFreeze™ Cryopreservation System to Accelerate the Development of Cell Therapies

March 19, 2025 | markets.businessinsider.com

Teknova and Pluristyx Launch Proprietary PluriFreeze™ Cryopreservation System to Accelerate the Development of Cell Therapies

March 19, 2025 | globenewswire.com

Teknova, Pluristyx announce collaboration over next-generation cell therapies

March 11, 2025 | markets.businessinsider.com

Teknova and Pluristyx Announce Collaboration to Streamline the Manufacture of Next-Generation Cell Therapies

March 11, 2025 | globenewswire.com

Earnings Update: Here's Why Analysts Just Lifted Their Alpha Teknova, Inc. (NASDAQ:TKNO) Price Target To US$10.67

March 8, 2025 | uk.finance.yahoo.com

BTIG Reaffirms Their Hold Rating on Alpha Teknova (TKNO)

March 6, 2025 | markets.businessinsider.com

Alpha Teknova, Inc. (NASDAQ:TKNO) Q4 2024 Earnings Call Transcript

March 6, 2025 | msn.com

Alpha Teknova’s Earnings Call: Growth Amid Challenges

March 5, 2025 | tipranks.com

Alpha Teknova, Inc. (TKNO) Q4 2024 Earnings Call Transcript

March 4, 2025 | seekingalpha.com

Alpha Teknova Reports Steady Revenue Growth in 2024

March 4, 2025 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TKNO, SPRY, GPCR, and OCUL Company Descriptions

Structure Therapeutics NASDAQ:GPCR

$20.62 +0.18 (+0.88%)

Closing price 03:10 PM Eastern

Extended Trading

$20.62 +0.00 (+0.00%)

As of 04:09 PM Eastern

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Ocular Therapeutix NASDAQ:OCUL

$9.36 -0.10 (-1.06%)

Closing price 01:45 PM Eastern

Extended Trading

$9.62 +0.26 (+2.78%)

As of 04:49 PM Eastern

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

ARS Pharmaceuticals NASDAQ:SPRY

$16.48 -0.27 (-1.58%)

Closing price 03:38 PM Eastern

Extended Trading

$16.52 +0.04 (+0.21%)

As of 04:43 PM Eastern

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

Alpha Teknova NASDAQ:TKNO

$5.22 +0.13 (+2.55%)

As of 01:19 PM Eastern

Alpha Teknova, Inc. produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions. Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time